在一片粉色的喧嚣中，线粒体生物能量学在帕金森病中扮演着主导角色。
In a flurry of PINK, mitochondrial bioenergetics takes a leading role in Parkinson's disease.
机构信息
Department of Pharmacology, MC 0636, Basic Sciences Building, Rm 3014, 9500 Gilman Dr., La Jolla, University of California, San Diego, CA 92093, USA.
出版信息
EMBO Mol Med. 2009 May;1(2):81-4. doi: 10.1002/emmm.200900020.
Abstract
For many years research in Parkinson's disease (PD) has linked mitochondrial dysfunction with the characteristic loss of dopaminergic neurons of the substantia nigra, accumulation of cytoplasmic inclusions termed Lewy bodies, and motor dysfunction (Henchcliffe & Beal, 2008). The most compelling connection is that Parkinsonism can be observed in both humans and animals following exposure to inhibitors of complex I of the electron transport chain (Betarbet et al, 2002).
摘要
多年来，帕金森病（PD）的研究将线粒体功能障碍与黑质中多巴胺能神经元的特征性丧失、称为路易体的细胞质包涵体的积累以及运动功能障碍联系起来（Henchcliffe 和 Beal，2008）。最引人注目的联系是，在接触电子传递链复合物 I 抑制剂后，人类和动物都可以观察到帕金森病（Betarbet 等人，2002）。
相似文献
1
In a flurry of PINK, mitochondrial bioenergetics takes a leading role in Parkinson's disease.
EMBO Mol Med. 2009 May;1(2):81-4. doi: 10.1002/emmm.200900020.
2
Stimulation of electron transport as potential novel therapy in Parkinson's disease with mitochondrial dysfunction.
Biochem Soc Trans. 2015 Apr;43(2):275-9. doi: 10.1042/BST20140325.
3
Mitochondrial control of cell bioenergetics in Parkinson's disease.
Free Radic Biol Med. 2016 Nov;100:123-137. doi: 10.1016/j.freeradbiomed.2016.04.012. Epub 2016 Apr 16.
4
Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases.
J Neurol Sci. 1998 Jun 11;158(1):24-9. doi: 10.1016/s0022-510x(98)00095-1.
5
Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms.
Brain. 2013 Aug;136(Pt 8):2369-78. doi: 10.1093/brain/awt196.
6
Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease.
Exp Neurol. 2009 Aug;218(2):235-46. doi: 10.1016/j.expneurol.2009.03.006. Epub 2009 Mar 18.
7
Metabolic Dysfunction in Parkinson's Disease: Bioenergetics, Redox Homeostasis and Central Carbon Metabolism.
Brain Res Bull. 2017 Jul;133:12-30. doi: 10.1016/j.brainresbull.2017.03.009. Epub 2017 Mar 21.
8
Monitoring mitochondrial dynamics and complex I dysfunction in neurons: implications for Parkinson's disease.
Biochem Soc Trans. 2013 Dec;41(6):1618-24. doi: 10.1042/BST20130189.
9
Determinants of dopaminergic neuron loss in Parkinson's disease.
FEBS J. 2018 Oct;285(19):3657-3668. doi: 10.1111/febs.14607. Epub 2018 Aug 14.
10
Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson's disease.
Science. 2017 Sep 22;357(6357):1255-1261. doi: 10.1126/science.aam9080. Epub 2017 Sep 7.
引用本文的文献
1
Caffeine improves mitochondrial function in PINK1-null mutant Drosophila melanogaster.
J Bioenerg Biomembr. 2023 Feb;55(1):1-13. doi: 10.1007/s10863-022-09952-5. Epub 2022 Dec 10.
2
Complex I Controls Mitochondrial and Plasma Membrane Potentials in Nerve Terminals.
Neurochem Res. 2021 Jan;46(1):100-107. doi: 10.1007/s11064-020-02990-8. Epub 2020 Mar 4.
3
Autophagy Dysfunction and Oxidative Stress, Two Related Mechanisms Implicated in Retinitis Pigmentosa.
Front Physiol. 2018 Jul 26;9:1008. doi: 10.3389/fphys.2018.01008. eCollection 2018.
4
Perturbed autophagy and DNA repair converge to promote neurodegeneration in amyotrophic lateral sclerosis and dementia.
Brain. 2018 May 1;141(5):1247-1262. doi: 10.1093/brain/awy076.
5
The role of mitochondrial dysfunction in age-related diseases.
Biochim Biophys Acta. 2015 Nov;1847(11):1387-400. doi: 10.1016/j.bbabio.2015.05.021. Epub 2015 Jun 4.
6
Mitochondrial DNA damage as a peripheral biomarker for mitochondrial toxin exposure in rats.
Toxicol Sci. 2014 Dec;142(2):395-402. doi: 10.1093/toxsci/kfu185. Epub 2014 Sep 18.
7
Identifying the genetic components underlying the pathophysiology of movement disorders.
Appl Clin Genet. 2011 Jun 23;4:81-92. doi: 10.2147/TACG.S7333. Print 2011.
8
Metabolism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by mitochondrion-targeted cytochrome P450 2D6: implications in Parkinson disease.
J Biol Chem. 2013 Feb 8;288(6):4436-51. doi: 10.1074/jbc.M112.402123. Epub 2012 Dec 20.
本文引用的文献
1
Parkinson's disease mutations in PINK1 result in decreased Complex I activity and deficient synaptic function.
EMBO Mol Med. 2009 May;1(2):99-111. doi: 10.1002/emmm.200900006.
2
PINK1-associated Parkinson's disease is caused by neuronal vulnerability to calcium-induced cell death.
Mol Cell. 2009 Mar 13;33(5):627-38. doi: 10.1016/j.molcel.2009.02.013.
3
Loss of PINK1 function promotes mitophagy through effects on oxidative stress and mitochondrial fission.
J Biol Chem. 2009 May 15;284(20):13843-13855. doi: 10.1074/jbc.M808515200. Epub 2009 Mar 10.
4
Silencing of PINK1 expression affects mitochondrial DNA and oxidative phosphorylation in dopaminergic cells.
PLoS One. 2009;4(3):e4756. doi: 10.1371/journal.pone.0004756. Epub 2009 Mar 9.
5
PINK1 defect causes mitochondrial dysfunction, proteasomal deficit and alpha-synuclein aggregation in cell culture models of Parkinson's disease.
PLoS One. 2009;4(2):e4597. doi: 10.1371/journal.pone.0004597. Epub 2009 Feb 26.
6
Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation.
J Clin Invest. 2009 Mar;119(3):650-60. doi: 10.1172/JCI37617. Epub 2009 Feb 23.
7
Pink1 forms a multiprotein complex with Miro and Milton, linking Pink1 function to mitochondrial trafficking.
Biochemistry. 2009 Mar 10;48(9):2045-52. doi: 10.1021/bi8019178.
8
Molecular basis of Parkinson's disease.
Neuroreport. 2009 Jan 28;20(2):150-6. doi: 10.1097/WNR.0b013e32831c50df.
9
Loss-of-function analysis suggests that Omi/HtrA2 is not an essential component of the PINK1/PARKIN pathway in vivo.
J Neurosci. 2008 Dec 31;28(53):14500-10. doi: 10.1523/JNEUROSCI.5141-08.2008.
10
Bidirectional Ca2+-dependent control of mitochondrial dynamics by the Miro GTPase.
Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20728-33. doi: 10.1073/pnas.0808953105. Epub 2008 Dec 19.
Zotero 插件